241 related articles for article (PubMed ID: 27916903)
1. Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.
Wu CC; Huang YF; Hsieh CP; Chueh PJ; Chen YL
Molecules; 2016 Nov; 21(12):. PubMed ID: 27916903
[TBL] [Abstract][Full Text] [Related]
2. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
4. Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Ory B; Baud'huin M; Verrecchia F; Royer BB; Quillard T; Amiaud J; Battaglia S; Heymann D; Redini F; Lamoureux F
Clin Cancer Res; 2016 May; 22(10):2520-33. PubMed ID: 26712686
[TBL] [Abstract][Full Text] [Related]
5. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
7. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
Ory B; Moriceau G; Trichet V; Blanchard F; Berreur M; Rédini F; Rogers M; Heymann D
J Cell Mol Med; 2008 Jun; 12(3):928-41. PubMed ID: 18494934
[TBL] [Abstract][Full Text] [Related]
9. Ursolic Acid Triggers Apoptosis in Human Osteosarcoma Cells via Caspase Activation and the ERK1/2 MAPK Pathway.
Wu CC; Cheng CH; Lee YH; Chang IL; Chen HY; Hsieh CP; Chueh PJ
J Agric Food Chem; 2016 Jun; 64(21):4220-6. PubMed ID: 27171502
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83.
Ge XY; Yang LQ; Jiang Y; Yang WW; Fu J; Li SL
PLoS One; 2014; 9(6):e101207. PubMed ID: 24963720
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment.
Yazıcı T; Koçer G; Nazıroğlu M; Övey İS; Öz A
Biol Trace Elem Res; 2018 Aug; 184(2):358-368. PubMed ID: 29081061
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Kimura S; Kuroda J; Segawa H; Sato K; Nogawa M; Yuasa T; Ottmann OG; Maekawa T
Int J Hematol; 2004 Jan; 79(1):37-43. PubMed ID: 14979476
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Heymann D; Ory B; Blanchard F; Heymann MF; Coipeau P; Charrier C; Couillaud S; Thiery JP; Gouin F; Redini F
Bone; 2005 Jul; 37(1):74-86. PubMed ID: 15894525
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of bisphosphonates on osteosarcoma.
Ohba T; Cates JM; Cole HA; Slosky DA; Haro H; Ichikawa J; Ando T; Schwartz HS; Schoenecker JG
Bone; 2014 Jun; 63():110-20. PubMed ID: 24636958
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress plays an important role in zoledronic acid-induced autophagy.
Khandelwal VK; Mitrofan LM; Hyttinen JM; Chaudhari KR; Buccione R; Kaarniranta K; Ravingerová T; Mönkkönen J
Physiol Res; 2014; 63(Suppl 4):S601-12. PubMed ID: 25669691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
